3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
31
Solid Tumors
7
Unspecified Childhood Solid Tumor, Protocol Specific
6
Solid Tumor
6
Advanced Solid Tumor
6
Advanced Solid Tumors
4
Pediatric Solid Tumors
2
Pediatric Solid Tumor
2
Stomach Neoplasms
1
Solid Tumor, Unspecified, Adult
1
Solid Tumor Malignancy
1
Sarcoma
1
Relapsed Solid Tumors
1
Refractory Solid Tumors in Children
1
Refractory Solid Tumors
1
P1b: Advanced Solid Tumors
1
Neuroendocrine Tumors
1
Neoplasms
1
Mesothelioma
1
MSI-H Advanced Colorectal Cancer
1
Locally Advanced (Unresectable) or Metastatic Solid Tumors
1
Glioblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Childhood Solid Tumors
1
Carcinoma, Ovarian Epithelial
1
Advanced Solid Tumours
1
Interventions
adavosertib
5
durvalumab
3
Paclitaxel
3
olaparib
2
ceralasertib
2
Fluorouracil
2
Carboplatin
2
toripalimab
1
sintilimab
1
pembrolizumab
1
factor IX, factor VII, factor X, prothrombin drug combination
1
drug XX Z
1
danvatirsen
1
capivasertib
1
Rifampin
1
Pantoprazole
1
Omeprazole
1
Leucovorin
1
Itraconazole
1
Irinotecan
1
Injections
1
Gemcitabine
1
Doxorubicin
1
Cisplatin
1
AZD0156
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Solid Tumours
×
Irinotecan
×
Other solid neoplasm
×
Clear all
NCT02588105
2022-09-19
AToM
AstraZeneca
Phase 1
Completed
84 enrolled